HighTower Advisors LLC Sells 1,580 Shares of Ionis Pharmaceuticals, Inc. (IONS)

HighTower Advisors LLC lessened its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 14.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,659 shares of the company’s stock after selling 1,580 shares during the quarter. HighTower Advisors LLC’s holdings in Ionis Pharmaceuticals were worth $496,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Ionis Pharmaceuticals by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after purchasing an additional 417,364 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Ionis Pharmaceuticals by 4.0% during the 2nd quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after purchasing an additional 264,179 shares in the last quarter. State Street Corp grew its holdings in shares of Ionis Pharmaceuticals by 20.5% during the 1st quarter. State Street Corp now owns 3,340,471 shares of the company’s stock worth $134,285,000 after purchasing an additional 567,792 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Ionis Pharmaceuticals by 8.6% during the 1st quarter. Geode Capital Management LLC now owns 947,906 shares of the company’s stock worth $38,105,000 after purchasing an additional 75,027 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Ionis Pharmaceuticals by 6.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 736,989 shares of the company’s stock worth $29,627,000 after purchasing an additional 44,372 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://ledgergazette.com/2017/10/18/hightower-advisors-llc-sells-1580-shares-of-ionis-pharmaceuticals-inc-ions.html.

In related news, Chairman Stanley T. Crooke sold 11,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $55.35, for a total transaction of $608,850.00. Following the sale, the chairman now owns 48,014 shares of the company’s stock, valued at approximately $2,657,574.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Stanley T. Crooke sold 27,500 shares of the firm’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $52.89, for a total value of $1,454,475.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 90,268 shares of company stock worth $5,023,395. Company insiders own 2.13% of the company’s stock.

IONS has been the topic of several recent research reports. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price objective on the stock in a report on Monday, July 31st. Jefferies Group LLC reissued an “underperform” rating and set a $18.00 price objective (up previously from $17.00) on shares of Ionis Pharmaceuticals in a report on Thursday, August 10th. Sanford C. Bernstein initiated coverage on Ionis Pharmaceuticals in a report on Thursday, July 27th. They set a “market perform” rating and a $57.00 price objective on the stock. BMO Capital Markets reissued an “outperform” rating and set a $62.00 price objective (up previously from $59.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, July 12th. Finally, Barclays PLC decreased their price objective on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a report on Thursday, September 21st. Three analysts have rated the stock with a sell rating, six have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Ionis Pharmaceuticals has an average rating of “Hold” and an average price target of $50.04.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) opened at 63.85 on Wednesday. The company has a 50-day moving average price of $54.75 and a 200 day moving average price of $49.79. The firm has a market cap of $7.94 billion, a price-to-earnings ratio of 306.97 and a beta of 3.12. Ionis Pharmaceuticals, Inc. has a 52 week low of $24.58 and a 52 week high of $64.19.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.03). The business had revenue of $104.15 million during the quarter, compared to analyst estimates of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The company’s revenue for the quarter was up 170.7% compared to the same quarter last year. During the

Several other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Ionis Pharmaceuticals by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after purchasing an additional 417,364 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Ionis Pharmaceuticals by 4.0% during the 2nd quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after purchasing an additional 264,179 shares in the last quarter. State Street Corp grew its holdings in shares of Ionis Pharmaceuticals by 20.5% during the 1st quarter. State Street Corp now owns 3,340,471 shares of the company’s stock worth $134,285,000 after purchasing an additional 567,792 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Ionis Pharmaceuticals by 8.6% during the 1st quarter. Geode Capital Management LLC now owns 947,906 shares of the company’s stock worth $38,105,000 after purchasing an additional 75,027 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Ionis Pharmaceuticals by 6.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 736,989 shares of the company’s stock worth $29,627,000 after purchasing an additional 44,372 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://ledgergazette.com/2017/10/18/hightower-advisors-llc-sells-1580-shares-of-ionis-pharmaceuticals-inc-ions.html.

In related news, Chairman Stanley T. Crooke sold 11,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $55.35, for a total transaction of $608,850.00. Following the sale, the chairman now owns 48,014 shares of the company’s stock, valued at approximately $2,657,574.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Stanley T. Crooke sold 27,500 shares of the firm’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $52.89, for a total value of $1,454,475.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 90,268 shares of company stock worth $5,023,395. Company insiders own 2.13% of the company’s stock.

IONS has been the topic of several recent research reports. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price objective on the stock in a report on Monday, July 31st. Jefferies Group LLC reissued an “underperform” rating and set a $18.00 price objective (up previously from $17.00) on shares of Ionis Pharmaceuticals in a report on Thursday, August 10th. Sanford C. Bernstein initiated coverage on Ionis Pharmaceuticals in a report on Thursday, July 27th. They set a “market perform” rating and a $57.00 price objective on the stock. BMO Capital Markets reissued an “outperform” rating and set a $62.00 price objective (up previously from $59.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, July 12th. Finally, Barclays PLC decreased their price objective on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a report on Thursday, September 21st. Three analysts have rated the stock with a sell rating, six have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Ionis Pharmaceuticals has an average rating of “Hold” and an average price target of $50.04.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) opened at 63.85 on Wednesday. The company has a 50-day moving average price of $54.75 and a 200 day moving average price of $49.79. The firm has a market cap of $7.94 billion, a price-to-earnings ratio of 306.97 and a beta of 3.12. Ionis Pharmaceuticals, Inc. has a 52 week low of $24.58 and a 52 week high of $64.19.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.03). The business had revenue of $104.15 million during the quarter, compared to analyst estimates of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The company’s revenue for the quarter was up 170.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.47) EPS. Analysts expect that Ionis Pharmaceuticals, Inc. will post ($0.16) EPS for the current fiscal year.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply